The condition is today included in the group of RASopathies due to neurofibromin-mediated inactivation of the RAS/MAPK pathway (Figure 1), with secondary regulation of proliferation, differentiation, cell migration, and apoptosis [5,6]. Here, NF1 is linked to RASopathy.